Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Fibrillary glomerulonephritis combined with chronic inflammatory demyelinating polyneuropathy.
Resolution of Acute Disseminated Encephalomyelitis Following Termination of Pregnancy.
Ultrasound of inherited vs. acquired demyelinating polyneuropathies.
Correction: Predicting Relapsing-Remitting Dynamics in Multiple Sclerosis Using Discrete Distribution Models: A Population Approach.
Reliability and Repeatability of the Hoffmann Sign.
Diagnostic value of visual evoked potentials for clinical diagnosis of multiple sclerosis.
NFATc1 deficiency in T cells protects mice from experimental autoimmune encephalomyelitis.
Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.
Application of metabolomics in autoimmune diseases: Insight into biomarkers and pathology.
Measurement and maintenance of reserve in multiple sclerosis.
Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice.
A Long Term Analysis of The Clinical And Cost Effectiveness of Glatiramer Acetate From The Uk Multiple Sclerosis Risk Sharing Scheme.
Protective effect of naringin on 3-nitropropionic acid-induced neurodegeneration through the modulation of matrix metalloproteinases and glial fibrillary acidic protein.
Disease-modifying treatments for multiple sclerosis - a review of approved medications.
Proteomic analysis for early neurodegenerative biomarker detection in an animal model.
Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions.
Neuromyelitis Optica (NMO) with Abdominal Tuberculosis (TB).
Autoimmune disease: SIRT1 inhibition suppresses multiple sclerosis.
Lifestyle shapes the dialog between environment, microglia, and adult neurogenesis.
Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies - Perspectives for immunoadsorption.
Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis.
Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab.
Enhanced accumulation of Kir4.1 protein, but not mRNA, in a murine model of cuprizone-induced demyelination.
Pages
« first
‹ previous
…
696
697
698
699
700
701
702
703
704
…
next ›
last »